A novel antidepressant from Praxis Precision Medicines did not outperform placebo in a pivotal examine, the corporate stated Monday, casting doubt on what was meant to be a nuanced method to the mind’s pure regulatory system.
The drug, a once-daily oral remedy often called PRAX-114, missed its main and secondary targets in a examine enrolling about 200 sufferers with main depressive dysfunction. After two and 4 weeks of remedy, sufferers receiving PRAX-114 didn’t see their signs considerably enhance in comparison with placebo, the corporate stated. Praxis didn’t disclose particulars of the trial outcomes.
Unlock this text by subscribing to STAT+ and luxuriate in your first 30 days free!
